Umbilical-Derived Allograft Therapy

Your body repairs itself using signals, growth factors, and structural building blocks. An umbilical-derived allograft supplies a concentrated dose of those same materials, sourced from screened donor tissue rather than taken from you, to support your body’s own repair process.

What It Is

Umbilical-derived allografts are processed from donated umbilical cord tissue, most often the Wharton’s jelly, the gel-like connective tissue that cushions and protects the vessels inside the cord. This tissue is naturally rich in growth factors, cytokines, hyaluronic acid, and structural proteins like collagen, all of which play a role in tissue repair and inflammation regulation.

We want to be precise about terminology here, because this category of product is often marketed loosely as “stem cell therapy,” and that can be misleading. Independent lab analysis of commercial umbilical allograft products has found that the amount of viable, proliferative stem cells varies significantly between manufacturers and products, and many contain few or none. What’s more consistently present, and what the research points to as the likely source of benefit, is the tissue’s composition: growth factors, cytokines, hyaluronic acid, and extracellular matrix components that support your body’s own regenerative signaling. We use the term “umbilical-derived allograft” rather than “stem cell injection” because it’s the more accurate description of what’s actually in the product and how it likely works.

How It’s Sourced and Processed

Donor tissue is recovered from full-term, scheduled C-section deliveries with the mother’s informed consent, after extensive donor health and infectious disease screening. This is a different process from cord blood banking, which is stem cells collected for the baby’s own future use. The tissue we use is processed by an FDA-registered tissue bank under the American Association of Tissue Banks (AATB) standards and regulated by the FDA as a human cell and tissue product (an “HCT/P”) under Section 361 of the Public Health Service Act. That regulatory pathway requires the tissue to be minimally manipulated and used for a purpose consistent with its natural function, which in practical terms means the tissue is processed (typically dehydrated or cryopreserved) but not substantially altered, cultured, or expanded before it reaches you.

The Science Behind It

Wharton’s jelly, the connective tissue at the core of the umbilical cord, is dense with the biological materials your body uses to repair itself: a network of growth factors, cytokines, hyaluronic acid, scaffolding proteins, and extracellular matrix components. A few things about this tissue’s biology are worth knowing:

Sources: Sabapathy et al., “Human Wharton’s Jelly Mesenchymal Stem Cells Plasticity Augments Scar-Free Wound Healing,” PLoS One (2014); Gao et al., “Mesenchymal Stem Cells and Immunomodulation: Current Status and Future Prospects,” Cell Death and Disease (2016).

What It May Help With

Umbilical-derived allograft therapy is most often used to supplement tissue repair for patients dealing with:

• Osteoarthritis and joint degeneration
• Chronic tendon and ligament injuries
• Soft tissue and connective tissue damage that hasn’t responded to conservative care
• Cases where a patient’s own tissue (for PRP or similar autologous therapies) is less viable due to age, chronic illness, or a prior injury at the donor site

As with any regenerative therapy, individual results vary based on the extent of the damage, your overall health, and how your body responds. We’ll give you a realistic picture of what to expect during your evaluation, based on your imaging, history, and lab work.

What to Expect

An umbilical-derived allograft is delivered as an injection directly into or around the affected tissue, guided by ultrasound or palpation depending on the site. At Gateway, this injection is one part of our broader same-day protocol: we prime the tissue beforehand with modalities like deep tissue laser or shockwave therapy, deliver the injection, then follow up same-day with additional stimulatory treatment to support the response. The appointment itself typically takes under an hour, and most patients resume normal activity the same day with minimal restrictions.

Safety and What to Know

Because umbilical-derived allografts come from donor tissue rather than your own, some patients ask about rejection or disease transmission risk. We take that seriously, and the screening and processing standards behind this tissue are extensive:

• Donor screening. Tissue is recovered only from healthy, carefully screened mothers at the time of a scheduled delivery, with full informed consent.
• Infectious disease testing. Donor serology is tested at a CLIA-certified laboratory for markers including Hepatitis B (HBsAg, HBcAb), Hepatitis C (HCV), and HIV (HIV I/II antibody and HIV NAT), in accordance with the Clinical Laboratory Improvement Amendments (CLIA) and 42 CFR Part 493.
• cGMP processing. Tissue is processed in a current Good Manufacturing Practice (cGMP) facility, with sterility independently validated by a third-party accredited laboratory.
• Low immune risk. As covered above, this tissue type is naturally low in the markers that trigger immune rejection, which further reduces the likelihood of an adverse reaction.

As with any medical treatment, no outcome is guaranteed, and this therapy is not a replacement for a full diagnostic workup. We’ll walk through your specific risk factors and answer any questions before you decide whether it’s the right option for you.